SCYX SCYNEXIS, Inc.
SCYNEXIS, Inc. (SCYX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.40 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.8% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.
Sector
Healthcare
Industry
Drug Manufacturers/Other